Product Pathways - Neuroscience
CEND1 Antibody #9894
|9894S||100 µl (10 western blots)||---||In Stock||---|
|9894||carrier free and custom formulation / quantity||email request|
Already purchased this product? Write a Review.
|W||1:1000||Human, Mouse, Rat||Endogenous||22||Rabbit|
Species cross-reactivity is determined by western blot.
Applications Key: W=Western Blotting, IF-F=Immunofluorescence (Frozen)
Specificity / Sensitivity
CEND1 Antibody recognizes endogenous levels of total CEND1 protein.
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human CEND1 protein. Antibodies are purified by protein A and peptide affinity chromatography.
The progression of progenitor cells towards neuronal differentiation is regulated by cell cycle control and the transition from proliferative to neurogenic cell divisions. Cell cycle exit and neuronal differentiation 1 (CEND1) is a neuronal protein widely expressed in the adult nervous system (1). It is implicated in the synchronization of cell cycle exit and differentiation of neuronal precursors in the developing nervous system, and its expression marks the exit of proliferative cells from the cell cycle (2,3). Levels of CEND1 expression in the subventricular zone of the adult nervous system are critical for cell cycle control and neuronal differentiation mechanisms during neonatal SVZ neurogenesis (4). It has recently been shown that neural progenitor cells (NPCs) that overexpress CEND1 display increased neuronal differentiation in a mouse model of brain injury, suggesting its potential use as a therapeutic intervention for neurodegenerative diseases and brain injury (5).
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
DRAQ5® is a registered trademark of Biostatus Limited.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.